ムラガキ　ヨシヒロ   Muragaki Yoshihiro   村垣　善浩    所属   医学部 医学科（東京女子医科大学病院）    職種   客員教授
言語種別	英語
発表タイトル	Role of photodynamic therapy using talaporfin sodium and a semiconductor laser in patients with newly diagnosed glioblastoma
会議名	The 34th Japan Neurosurgery English Forum
学会区分	全国規模の学会
発表形式	口頭
講演区分	一般
発表者・共同発表者	◎FUKUI Atsushi, NITTA Masayuki, MURAGAKI Yoshihiro, MARUYAMA Takashi, ISEKI Hiroshi, KOMORI Takashi, IKUTA Soko, SAITO Taiichi, YASUDA Takayuki, HOSONO Junji , OKAMOTO Saori, KORIYAMA Shunichi, KAWAMATA Takakazu
発表年月日	2019/07/26
開催地 （都市, 国名）	Kawasaki, Japan
学会抄録	The 34th Japan Neurosurgery English Forum JNEF2019 Program&Abstract 22
概要	Objective: In this study on the effectiveness and safety of photodynamic therapy (PDT) using talaporfin sodium, the long-term follow-up results of 30 patients with newly diagnosed glioblastoma enrolled from 2009 to 2016 were analyzed and compared with those of 164 patients treated without PDT during the same period. Methods: The main outcome measures were the median overall survival (OS) and progression-free survival (PFS) times. Moreover, the adverse events and radiological changes after PDT, as well as the patterns of recurrence, were compared between the groups. Univariate and multivariate analyses were performed to identify the prognostic factors, including PDT, among patients with newly diagnosed glioblastoma. Results: The median PFS times of the PDT and control groups were 19.6 and 9.0 months respectively (p = 0.016). The median OS times were 27.4 and 22.1 months respectively (p = 0.0327). Multivariate analyses found PDT, preoperative Karnofsky Performance Scale score, and IDH mutation to be significant independent prognostic factors for both OS and PFS. Eighteen of 30 patients in the PDT group experienced tumor recurrence, including local recurrence, distant recurrence, and dissemination in 10, 3, and 4 patients, respectively. Conversely, 141 of 164 patients in the control group experienced tumor recurrence, including 101 cases of local recurrence. The rate of local recurrence tended to be lower in the PDT group (p = 0.06). Conclusions: The results of the present study suggest that PDT with talaporfin sodium provides excellent local control, with few adverse effects even in cases of multiple laser irradiations, as well as potential survival benefits for patients with newly diagnosed glioblastoma.